Chicago lab owner pleads guilty, cooperating against ex-Loretto Hospital executive in COVID-19 test scheme

A Chicago lab owner pleaded guilty Wednesday to conspiring with fugitive ex-Loretto Hospital executive Anosh Ahmed in a COVID ...
Smithsonian Magazine

The First At-Home Test for Infected Ticks Could Improve Lyme Disease Diagnosis

LymeAlert will hit the market in August. The latest tool against the tick-borne illness could become a medicine cabinet ...
Everyday Health

Cuts, Scrapes, or Sprains? These Are the 9 Best First Aid Kits to Keep at Home and On the Go

Everyday Health independently vets all recommended products. If you purchase a featured product, we may be compensated. Learn why you can trust us. Everyday Health independently vets all recommended ...

Why one a hard-right Texas lawmaker is in Anthony Fauci's diaries

Why is Texas Rep. Brian Harrison, one of the lege's loudest members, in Anthony Fauci's pandemic diary?
Fox News

Fauci privately took credit for COVID-19 lockdowns despite public denial, newly exposed diary entries reveal

Despite denying on multiple occasions during and after the COVID-19 pandemic that he personally recommended lockdowns, excerpts revealed from Dr. Anthony Fauci's private diary prove a clear ...
The Business Journals

Freenome went public for $300 million, then scored a huge victory with colorectal cancer test

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min SimpleScreen CRC is a simple ...
MD&M East

Freenome's Blood Test for Colorectal Cancer Receives FDA Approval; Abbott to Commercialize

FDA has approved Freenome’s Simple Screen CRC, a blood-based test for colorectal cancer. Abbott Laboratories will exclusively commercialize the test in the U.S. in the fall, according to a release.
BioSpace

FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.

BRISBANE, Calif. and ABBOTT PARK, Ill., July 27, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, and Abbott (NYSE: ABT ...
FierceBiotech

FDA approves Freenome colorectal cancer blood test to be marketed by Abbott

The FDA has approved Freenome’s new blood-based colorectal cancer test, SimpleScreen CRC, which Abbott will exclusively market in the U.S. Abbott will pay Freenome $100 million as part of a 2025 deal ...
Reuters

Abbott investigates two separate cyber incidents, says no operations affected

July 17 (Reuters) - Abbott Laboratories (ABT.N), opens new tab is investigating two cyber incidents involving unauthorized access to some internal systems at its cancer diagnostics business and ‌its ...
Bleeping Computer

Abbott probes two cyber incidents amid extortion claims

Abbott Laboratories is investigating two separate cybersecurity incidents after confirming unauthorized access to internal legacy Exact Sciences systems in its Cancer Diagnostics business, while also ...
medtechdive

Abbott discloses cyberattack on cancer diagnostics business

Abbott disclosed on Thursday that a cyberattack hit its cancer diagnostics business. The medical device company said in a statement posted to its website that there was unauthorized access to a ...